STOCK TITAN

CollPlant Biotechnologies (CLGN) Stock News, Feb-Sep 2026

CLGN NASDAQ

CollPlant Biotechnologies Ltd. develops regenerative and aesthetic medicine technologies based on plant-derived recombinant human collagen, or rhCollagen. News about CLGN centers on its BioInk and 3D bioprinting portfolio, including Collink.3D and BioFlex, as well as medical aesthetics programs such as photocurable dermal filler technology and tissue-regeneration applications.

Company updates also cover operating and financial results, distribution expansion for rhCollagen and BioInk products, Vergenix STR commercialization, intellectual-property activity, collaboration developments, capital actions and Nasdaq listing-compliance matters.

News
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) announced that its board has approved a one-for-ten reverse share split of its ordinary shares, following shareholder approval at the August 18, 2026 extraordinary general meeting. The split will take effect at the opening of trading on September 4, 2026, when CLGN will begin trading on a split-adjusted basis.

According to CollPlant, the reverse split is part of its strategic plan to regain compliance with Nasdaq’s minimum bid price requirement. Fractional shares will be rounded to the nearest whole share, and all outstanding options and warrants will be proportionately adjusted. The new CUSIP will be M2R51X124.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.86%
Tags
-
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) signed a definitive agreement to acquire Israeli deep-tech company LightSolver, which is developing a pure photonic computing architecture centered on its Laser Processing Unit™ (LPU™). The LPU is designed as an all-optical computing layer alongside CPUs and GPUs, targeting high-intensity workloads in simulation, optimization and Physical AI, with commercial availability targeted for 2028.

According to CollPlant, consideration includes 3,734,476 new ordinary shares (19.7% of pre-deal share capital), pre-funded warrants for 6,134,363 shares, and milestone-based warrants for 224,078,345 shares, plus rollover options for 2,261,966 shares, largely exercisable upon LightSolver achieving specified technological and commercial milestones and subject to shareholder approval above an equity blocker.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.35%
Tags
-
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) entered a definitive agreement for a $2.6 million private placement, issuing 7,647,061 ordinary shares (or equivalents) plus series A and B warrants. Securities are priced at $0.34 per share and accompanying warrants, with closing expected on or about July 1, 2026.

Series A and B warrants, both with a $0.34 exercise price, cover up to 22,941,183 shares in total and become exercisable on the shareholder approval date. Net proceeds will fund working capital, R&D and evaluation of strategic transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
private placement
Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN) reported Q1 2026 GAAP revenue of $73,000, down from $2.1 million in Q1 2025, mainly due to a non-recurring $2.0 million milestone last year. GAAP net loss widened to $3.1 million ($0.23/share). Cash and equivalents were $4.3 million after a $1.7 million February 2026 offering.

The company advanced its rhCollagen-based medical aesthetics pipeline, including a photocurable dermal filler in final preclinical stage, gained a Korean patent on this technology, launched the BioFlex DLP bioprinting kit, cut operating expenses via a ~50% headcount reduction, and began reviewing strategic alternatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
News
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) announced termination of its development agreement with AbbVie and a companywide cost-reduction plan including ~50% workforce reduction. The company said the actions extend its cash runway into Q4 2026 and it is actively pursuing new strategic partners across aesthetics while advancing three core programs: regenerative fillers, breast implants, and rhCollagen bioinks.

CollPlant also launched the BioFlex DLP bioink kit and expanded North American distribution via a cGMP logistics hub to support clinical supplies and commercial growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.71%
Tags
none
-
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) reported 2025 results: GAAP revenue $2.37M vs $0.52M in 2024, driven by a $2.0M AbbVie milestone. GAAP net loss narrowed to $11.5M ($0.94/sh) from $16.6M. Cash was $5.6M at year-end amid a 25% workforce reduction and cost‑cutting.

Operational highlights include new patents in the U.S., South Korea and Japan, BioFlex launch for DLP bioprinting, expanded North American distribution, and encouraging preclinical data for regenerative breast implants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.02%
Tags
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) received a Nasdaq notice on March 23, 2026, for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2). The company has a 180-calendar day cure period until September 21, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days.

The company may seek a second 180-day period if it meets market value and other initial listing standards and notifies Nasdaq of intent to cure, potentially via a reverse share split. Ordinary shares remain listed and tradable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.50%
Tags
none
-
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) launched a redesigned corporate website on March 18, 2026 to centralize investor, partner, and stakeholder information. The site expands details on the company's rhCollagen technology, product pipeline (breast implants, dermal fillers, bioinks), collaborations, SEC filings, and governance.

The update aims to improve transparency, accessibility, and engagement as CollPlant advances its clinical and preclinical programs and commercialization objectives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) said it will report full-year 2025 financial results on Thursday, March 26, 2026, before the opening of U.S. financial markets. The announcement sets a date for earnings disclosure and signals when investors can expect results and related company materials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
earnings date
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) announced the Korean Patent Office allowed a patent for its photocurable dermal filler covering a polymerizable rhCollagen solution for in situ light-activated tissue augmentation.

The allowance extends protection through 2039, follows a recent Japanese grant, and adds to granted patents in the US, Europe, China, Brazil, Australia, and Israel. According to the company, the global injectable soft-tissue filler market exceeds $6 billion. CollPlant noted a 2021 development and global commercialization agreement with Allergan (AbbVie).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.90%
Tags
none

FAQ

What is the current stock price of CollPlant Biotechnologies (CLGN)?

CollPlant Biotechnologies (CLGN) last closed at $4.64.

What is the market cap of CollPlant Biotechnologies (CLGN)?

The market cap of CollPlant Biotechnologies (CLGN) is approximately $14.3M.